2023 Q4 Form 10-K Financial Statement

#000114036124016612 Filed on March 29, 2024

View on sec.gov

Income Statement

Concept 2023 Q4 2023 2022
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $251.6K $1.512M $948.2K
YoY Change 12.86% 59.52%
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $251.6K $1.512M $948.2K
YoY Change 12.86% 59.52% 266.03%
Operating Profit -$1.512M -$948.2K
YoY Change 59.52%
Interest Expense $520.5K $5.299M $3.383M
YoY Change -73.77% 56.65%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income $268.9K $3.787M $2.435M
YoY Change -84.73% 55.53% -1039.9%
Income Tax $0.00 $0.00
% Of Pretax Income 0.0% 0.0%
Net Earnings $268.9K $3.787M $2.435M
YoY Change -84.73% 55.53% -1039.9%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share $0.03 $0.23 $0.08
COMMON SHARES
Basic Shares Outstanding
Diluted Shares Outstanding

Balance Sheet

Concept 2023 Q4 2023 2022
SHORT-TERM ASSETS
Cash & Short-Term Investments $409.6K $409.6K $946.3K
YoY Change -56.71% -56.71% -34.3%
Cash & Equivalents $409.6K
Short-Term Investments
Other Short-Term Assets $16.64K $16.64K $208.6K
YoY Change -92.02% -15.99%
Inventory
Prepaid Expenses $16.64K
Receivables
Other Receivables
Total Short-Term Assets $426.3K $426.3K $1.155M
YoY Change -63.09% -63.09% -31.61%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $44.29M $44.29M $238.0M
YoY Change -81.39% -81.39% 1.44%
Other Assets $0.00
YoY Change -100.0%
Total Long-Term Assets $44.29M $44.29M $238.0M
YoY Change -81.39% -81.39% 1.36%
TOTAL ASSETS
Total Short-Term Assets $426.3K $426.3K $1.155M
Total Long-Term Assets $44.29M $44.29M $238.0M
Total Assets $44.72M $44.72M $239.1M
YoY Change -81.3% -81.3% 1.12%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $42.05K $42.05K $2.100K
YoY Change 1902.38% 1902.38% -98.16%
Accrued Expenses $1.077M $1.077M $333.1K
YoY Change 223.35% 223.35% 5414.74%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $1.119M $1.119M $335.2K
YoY Change 233.87% 233.87% 179.05%
LONG-TERM LIABILITIES
Long-Term Debt $4.600M $4.600M $4.600M
YoY Change 0.0% 0.0% 0.0%
Other Long-Term Liabilities $8.050M $8.050M $8.050M
YoY Change 0.0% 0.0% 0.0%
Total Long-Term Liabilities $12.65M $12.65M $12.65M
YoY Change 0.0% 0.0% 0.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $1.119M $1.119M $335.2K
Total Long-Term Liabilities $12.65M $12.65M $12.65M
Total Liabilities $13.77M $13.77M $12.99M
YoY Change 6.04% 6.04% 1.68%
SHAREHOLDERS EQUITY
Retained Earnings -$13.34M
YoY Change 12.78%
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $30.95M $30.95M $226.2M
YoY Change
Total Liabilities & Shareholders Equity $44.72M $44.72M $239.1M
YoY Change -81.3% -81.3% 1.12%

Cashflow Statement

Concept 2023 Q4 2023 2022
OPERATING ACTIVITIES
Net Income $268.9K $3.787M $2.435M
YoY Change -84.73% 55.53% -1039.9%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$166.7K -$536.7K -$494.0K
YoY Change -11.15% 8.64% -17.3%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities $1.850K $199.0M $0.00
YoY Change -100.0%
Cash From Investing Activities $1.850K $199.0M $0.00
YoY Change -100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net -$1.850K -$199.0M $0.00
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -1.850K -199.0M 0.000
YoY Change -100.0%
NET CHANGE
Cash From Operating Activities -166.7K -536.7K -494.0K
Cash From Investing Activities 1.850K 199.0M 0.000
Cash From Financing Activities -1.850K -199.0M 0.000
Net Change In Cash -166.7K -536.7K -494.0K
YoY Change -11.15% 8.64% -134.3%
FREE CASH FLOW
Cash From Operating Activities -$166.7K -$536.7K -$494.0K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
-10882188
CY2023Q4 us-gaap Assets
Assets
44716401
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
42046
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1077056
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
1119102
CY2023Q4 us-gaap Liabilities
Liabilities
13769102
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
0
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
44716401
CY2022 us-gaap Operating Income Loss
OperatingIncomeLoss
-948157
CY2022Q4 us-gaap Cash
Cash
946299
CY2023Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
16640
CY2023Q4 us-gaap Assets Current
AssetsCurrent
426283
CY2022Q4 us-gaap Assets Current
AssetsCurrent
1154847
CY2023Q4 us-gaap Assets Held In Trust Noncurrent
AssetsHeldInTrustNoncurrent
44290118
CY2022Q4 us-gaap Assets Held In Trust Noncurrent
AssetsHeldInTrustNoncurrent
237982862
CY2022Q4 us-gaap Assets
Assets
239137709
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2100
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
333092
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
335192
CY2023Q4 dpcs Deferred Underwriting Fee Payable Noncurrent
DeferredUnderwritingFeePayableNoncurrent
8050000
CY2022Q4 dpcs Deferred Underwriting Fee Payable Noncurrent
DeferredUnderwritingFeePayableNoncurrent
8050000
CY2022Q4 us-gaap Liabilities
Liabilities
12985192
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
0
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-13343394
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-11830920
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-13342819
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-11830345
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
239137709
CY2023 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1512474
CY2022 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
948157
CY2023 us-gaap Operating Income Loss
OperatingIncomeLoss
-1512474
CY2023 us-gaap Investment Income Interest
InvestmentIncomeInterest
5299109
CY2022 us-gaap Investment Income Interest
InvestmentIncomeInterest
3382862
CY2023 us-gaap Net Income Loss
NetIncomeLoss
3786635
CY2022 us-gaap Net Income Loss
NetIncomeLoss
2434705
CY2022 dpcs Redeemable Ordinary Shares Accretion To Redemption Value
RedeemableOrdinarySharesAccretionToRedemptionValue
-3382862
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-11830345
CY2023 us-gaap Net Income Loss
NetIncomeLoss
3786635
CY2022 us-gaap Net Income Loss
NetIncomeLoss
2434705
CY2023 us-gaap Investment Income Interest
InvestmentIncomeInterest
5299109
CY2022 us-gaap Investment Income Interest
InvestmentIncomeInterest
3382862
CY2023 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-191908
CY2022 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-25452
CY2022 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-213631
CY2023 us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
39946
CY2022 us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
-111977
CY2023 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
743964
CY2022 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
327051
CY2023 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-536656
CY2022 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-494000
CY2023 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
198991853
CY2022 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
0
CY2022 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
0
CY2023 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-536656
CY2022 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-494000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
946299
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1440299
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
409643
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
946299
CY2023 dpcs Accretion Of Ordinary Shares To Redemption Value
AccretionOfOrdinarySharesToRedemptionValue
5299109
CY2022 dpcs Accretion Of Ordinary Shares To Redemption Value
AccretionOfOrdinarySharesToRedemptionValue
3382862
CY2023 us-gaap Use Of Estimates
UseOfEstimates
<div style="text-align: justify; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">Use of Estimates</div> <div style="font-family: 'Times New Roman'; font-size: 10pt;"> </div> <div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;">The preparation of the financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of income and expenses during the reporting period.</div> <div style="font-family: 'Times New Roman'; font-size: 10pt;"> </div> <div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;">Making estimates requires management to exercise significant judgement. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statements, which management considered in formulating its estimates, could change in the near term. Accordingly, the actual results could differ significantly from those estimates.</div>
CY2023 us-gaap Derivatives Embedded Derivatives
DerivativesEmbeddedDerivatives
<div style="text-align: justify; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">Sponsor Loan</div> <div style="font-family: 'Times New Roman'; font-size: 10pt;"> </div> <div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"><span style="letter-spacing: normal; text-indent: 0px; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">When the Company issues convertible debt it first evaluates the balance sheet classification of the convertible instrument in its entirety to determine whether the instrument should be classified as a liability under ASC 480 and second whether the conversion feature should be accounted for separately from the host instrument. A conversion feature of a convertible debt instrument or certain convertible preferred stock would be separated from the convertible instrument and classified as a derivative liability if the conversion feature, were it a stand-alone instrument, meets the definition of an “embedded derivative” as defined in ASC 815. Generally, characteristics that require derivative treatment include, among others, when the conversion feature is not indexed to the Company’s equity, as defined in ASC 815-40, or when it must be settled either in cash or by issuing stock that is readily convertible to cash. When a conversion feature meets the definition of an embedded derivative, it would be separated from the host instrument and classified as a derivative liability carried on the balance sheet at fair value, with any changes in its fair value recognized currently in the statement of operations. The Sponsor Loan has a conversion feature that allows for converting the loan into warrants. The Company performed an evaluation as outlined and determined that it qualifies for exemption as an equity instrument and is not bifurcated.</span></div>
CY2023 dei Amendment Flag
AmendmentFlag
false
CY2023 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2023 dei Entity Central Index Key
EntityCentralIndexKey
0001857803
CY2023 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
00-0000000
CY2022Q4 us-gaap Notes Payable Noncurrent Related Party Type Extensible Enumeration
NotesPayableNoncurrentRelatedPartyTypeExtensibleEnumeration
http://fasb.org/us-gaap/2023#RelatedPartyMember
CY2023Q4 us-gaap Notes Payable Noncurrent Related Party Type Extensible Enumeration
NotesPayableNoncurrentRelatedPartyTypeExtensibleEnumeration
http://fasb.org/us-gaap/2023#RelatedPartyMember
CY2023 dei Auditor Firm
AuditorFirmId
688
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023 dei Document Type
DocumentType
10-K
CY2023 dei Document Annual Report
DocumentAnnualReport
true
CY2023 dei Document Period End Date
DocumentPeriodEndDate
2023-12-31
CY2023 dei Document Transition Report
DocumentTransitionReport
false
CY2023 dei Entity File Number
EntityFileNumber
001-41041
CY2023 dei Entity Registrant Name
EntityRegistrantName
DP CAP ACQUISITION CORP I
CY2023 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
E9
CY2023 dei Entity Address Address Line1
EntityAddressAddressLine1
341 Newbury St,
CY2023 dei Entity Address Address Line2
EntityAddressAddressLine2
6th Floor
CY2023 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02115
CY2023 dei Entity Address City Or Town
EntityAddressCityOrTown
Boston
CY2023 dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
CY2023 dei City Area Code
CityAreaCode
617
CY2023 dei Local Phone Number
LocalPhoneNumber
874-5152
CY2023 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2023 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2023 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2023 dei Entity Small Business
EntitySmallBusiness
true
CY2023 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2023 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2023 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2023 dei Document Fin Stmt Error Correction Flag
DocumentFinStmtErrorCorrectionFlag
false
CY2023 dei Entity Shell Company
EntityShellCompany
true
CY2023Q2 dei Entity Public Float
EntityPublicFloat
42826691
CY2023Q4 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false
CY2023Q4 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2023Q4 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2023Q4 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2023 dei Auditor Name
AuditorName
Marcum LLP
CY2023 dei Auditor Location
AuditorLocation
New York
CY2023Q4 us-gaap Cash
Cash
409643
CY2022Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
208548
CY2023Q4 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
4600000
CY2022Q4 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
4600000
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-11830345
CY2023 dpcs Adjustment To Additional Paid In Capital Capital Contribution By Sponsor
AdjustmentToAdditionalPaidInCapitalCapitalContributionBySponsor
2791710
CY2023 dpcs Adjustment To Additional Paid In Capital Cost Of Raising Capital
AdjustmentToAdditionalPaidInCapitalCostOfRaisingCapital
2791710
CY2023 dpcs Redeemable Ordinary Shares Accretion To Redemption Value
RedeemableOrdinarySharesAccretionToRedemptionValue
-5299109
CY2023 us-gaap Net Income Loss
NetIncomeLoss
3786635
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-13342819
CY2022 us-gaap Net Income Loss
NetIncomeLoss
2434705
CY2023 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
0
CY2023 dpcs Proceeds From Cash Withdrawal From Trust Account
ProceedsFromCashWithdrawalFromTrustAccount
198991853
CY2022 dpcs Proceeds From Cash Withdrawal From Trust Account
ProceedsFromCashWithdrawalFromTrustAccount
0
CY2023 us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
198991853
CY2022 us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
0
CY2023 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-198991853
CY2023 dpcs Capital Contribution From Sponsor
CapitalContributionFromSponsor
2791710
CY2022 dpcs Capital Contribution From Sponsor
CapitalContributionFromSponsor
0
CY2023 dpcs Offering Costs Associated With Non Redemption Agreement
OfferingCostsAssociatedWithNonRedemptionAgreement
2791710
CY2022 dpcs Offering Costs Associated With Non Redemption Agreement
OfferingCostsAssociatedWithNonRedemptionAgreement
0
CY2021Q4 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
234600000
dpcs Cash Deposited In Trust Account Per Unit
CashDepositedInTrustAccountPerUnit
10.2
dpcs Cash Deposited In Trust Account Per Unit
CashDepositedInTrustAccountPerUnit
10.2
CY2023 dpcs Percentage Of Public Shares That Would Not Be Redeemed If Business Combination Is Not Completed Within Initial Combination Period
PercentageOfPublicSharesThatWouldNotBeRedeemedIfBusinessCombinationIsNotCompletedWithinInitialCombinationPeriod
1
dpcs Cash Deposited In Trust Account Per Unit
CashDepositedInTrustAccountPerUnit
10.2
dpcs Cash Deposited In Trust Account Per Unit
CashDepositedInTrustAccountPerUnit
10.2
CY2023Q4 dpcs Working Capital Deficit
WorkingCapitalDeficit
-692819
CY2023Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
0
CY2022Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
0
CY2023Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0
CY2023Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2023Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2023 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2021Q4 dpcs Payments For Underwriting Discount Per Unit
PaymentsForUnderwritingDiscountPerUnit
0.2
CY2021Q4 us-gaap Payments For Underwriting Expense
PaymentsForUnderwritingExpense
4600000
CY2021Q4 dpcs Deferred Underwriting Fee Per Unit
DeferredUnderwritingFeePerUnit
0.35
CY2021Q4 dpcs Deferred Underwriting Fee Payable Noncurrent
DeferredUnderwritingFeePayableNoncurrent
8050000
us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
230000000
us-gaap Temporary Equity Accretion To Redemption Value
TemporaryEquityAccretionToRedemptionValue
24239238
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3
0
CY2022 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3
0
CY2022 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3
0
CY2023 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3
0

Files In Submission

Name View Source Status
0001140361-24-016612-index-headers.html Edgar Link pending
0001140361-24-016612-index.html Edgar Link pending
0001140361-24-016612.txt Edgar Link pending
0001140361-24-016612-xbrl.zip Edgar Link pending
dpcs-20231231.xsd Edgar Link pending
ef20015349_10k.htm Edgar Link pending
ef20015349_ex10-8.htm Edgar Link pending
ef20015349_ex31-1.htm Edgar Link pending
ef20015349_ex31-2.htm Edgar Link pending
ef20015349_ex32-1.htm Edgar Link pending
ef20015349_ex32-2.htm Edgar Link pending
ef20015349_ex4-5.htm Edgar Link pending
ef20015349_ex97-1.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
dpcs-20231231_cal.xml Edgar Link unprocessable
dpcs-20231231_def.xml Edgar Link unprocessable
dpcs-20231231_lab.xml Edgar Link unprocessable
dpcs-20231231_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
ef20015349_10k_htm.xml Edgar Link completed
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending